Bionomics Ltd (OTCMKTS: BNOEF) is a clinical‐stage biopharmaceutical company headquartered in Adelaide, South Australia, that focuses on the discovery and development of novel small‐molecule therapies across neuroscience, oncology and immunology. Utilizing its proprietary IonX™ ion channel platform, the company identifies and optimizes compounds that modulate key biological targets with the aim of addressing areas of high unmet medical need.
The company’s lead programs include BNC210, a selective anxiolytic in development for the treatment of post‐traumatic stress disorder and other anxiety‐related conditions, and BNC105P, a vascular disrupting agent designed to target tumor blood vessels in oncology indications. In addition to internal research, Bionomics has established strategic collaborations with major pharmaceutical partners to advance and commercialize its pipeline candidates.
Founded in 1994 as a spin‐out from Flinders University, Bionomics has expanded its research and development capabilities with operations in Australia and liaison offices in the United States. Over the years, the company has engaged in multiple licensing agreements and research partnerships aimed at leveraging its ion channel expertise and accelerating clinical progress.
Under long‐standing leadership, including former Chief Executive Officer Dr. Deborah Rathjen, Bionomics has built a diversified portfolio of preclinical and clinical assets. The company’s management team comprises professionals with extensive drug discovery, clinical development and commercialization experience.
AI Generated. May Contain Errors.
